ARS Pharmaceuticals, Inc. Stock News

ARS Pharmaceuticals (NASDAQ: SPRY ) just reported results for the first quarter of 2024. ARS Pharmaceuticals reported earnings per share of -11 cents.

ARS Pharmaceuticals, Inc. (SPRY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yet again, the Oracle of Omaha has bolstered his stake in a media giant's tracking stocks.

ARS Pharmaceuticals, Inc. (SPRY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Finding  undervalued stocks is one of the key elements to making successful investments. Undervalued stocks are those that trade below their intrinsic value, meaning that the market has not fully re

SAN DIEGO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients fr

ARS Pharmaceuticals, Inc. received a surprise Complete Response Letter from the FDA for its epinephrine nasal spray, neffy. The FDA's concern was that ARS Pharma did not conduct efficacy trials for ne

When constructing a watch list of penny stocks, it is wise to closely monitor any legal insider trading activity. Though the rules surrounding insider trades are complex, legal filings by company exec

Both ARS Pharmaceuticals and Aquestive Therapeutics are developing non-injectable epinephrine products for anaphylaxis, with potential to capture significant market share from current standard (auto-i

ARS Pharmaceutical is seeking the approval of Neffy, a nasal spray version of epinephrine. The FDA is seeking additional dosing studies before approving Neffy.

Sharesof ARS Pharmaceuticals Inc. SPRY plunged 46.9% toward a 15-month low in premarket trading Wednesday, after the biopharmaceutical company said the U.S. Food and Drug Administration issued a Compl

ARS Pharmaceuticals (SPRY) gains as it gets favorable votes from the FDA advisory committee for epinephrine spray to treat severe allergic reactions.